Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.

Nemunaitis J, Eiseman I, Cunningham C, Senzer N, Williams A, Lenehan PF, Olson SC, Bycott P, Schlicht M, Zentgraff R, Shin DM, Zinner RG. Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res. 2005 May 15; 11(10):3846-53.

View in: PubMed